Natural alkaloid; anti-inflammatory; anti-parasitic
(±)-Stylopine hydrochloride targets inflammatory pathways and microbial pathogens. Its anti-inflammatory activity is mediated through modulation of oxidative stress and inhibition of inflammatory mediators. The compound exhibits antimicrobial activity against various pathogens. Its antitumor activity may involve induction of apoptosis and inhibition of cell proliferation.

Tetrahydrocoptisine (THC) significantly inhibited LPS-induced TNF-α, interleukin-6(IL-6) and nitric oxide (NO) production. THC inhibited the production of TNF-α and IL-6 by down-regulating LPS-induced IL-6 and TNF-α mRNA expression. Furthermore, it attenuated the phosphorylation of p38 mitogen-activated protein kinase (p38MAPK) and phosphorylation of extracellular signal-regulated kinase1/2 (ERK1/2) as well as the expression of nuclear factor kappa B(NF-κB), in a concentration-dependent manner. Taken together, our data suggest that THC is an active anti-inflammatory constituent by inhibition of TNF-α, IL-6 and NO production possibly via down-regulation of NF-κB activation, phospho-ERK1/2 and phospho-p38MAPK signal pathways[1].

---

(±)-Stylopine hydrochloride demonstrates in vitro anti-inflammatory, antimicrobial, and antitumor activities. It modulates oxidative stress and inhibits inflammatory mediators. The compound's activity is typically assessed in cell-based assays measuring cytokine production, microbial growth inhibition, and cancer cell viability.

The extracts or constituents from Corydalis impatiens are known to have many pharmacological activities. Tetrahydrocoptisine (THC), a protoberberine compound from Corydalis impatiens, was found to possess a potent anti-inflammatory effect in different acute or chronic inflammation model animals. Pretreatment with THC (i.p.) inhibited the paw and ear edema in the carrageenan-induced paw edema assay and xylene-induced ear edema assay, respectively. In the lipopolysaccharide (LPS)-induced systemic inflammation model, THC significantly inhibited serum tumor necrosis factor-alpha (TNF-α) release in mice [1].

---

Excessive alcohol consumption can lead to gastric ulcer and the present work was aimed to examine the protective effect of tetrahydrocoptisine (THC) in the model of ethanol-induced gastric ulcer in mice. Fasted mice treated with ethanol 75% (0.5ml/100g) were pre-treated with THC (10 or 20mg/kg, ip), cimetidine (100mg/kg, ip) or saline in different experimental sets for a period of 3days, and animals were euthanized 4h after ethanol ingestion. Gross and microscopic lesions, immunological and biochemical parameters were taken into consideration. The results showed that ethanol induced gastric damage, improving nitric oxide (NO) level, increased pro-inflammatory cytokine (TNF-α and IL-6) levels and myeloperoxidase (MPO) activity, as well as the expression of nuclear factor-κB (NF-κB) in the ethanol group. Pretreatment of THC at doses of 10 and 20mg/kg bodyweight significantly attenuated the gastric lesions as compared to the ethanol group. These results suggest that the gastroprotective activity of THC is attributed to reducing NO production and adjusting the pro-inflammatory cytokine, inhibited neutrophil accumulation and NF-κB expression[2].

---

In vivo activity of (±)-stylopine hydrochloride has been suggested by its traditional use in treating various conditions. Its anti-inflammatory, antimicrobial, and antitumor activities suggest potential for in vivo efficacy in models of inflammation, infection, and cancer. Further in vivo studies are needed to evaluate its therapeutic potential.

Assay of myeloperoxidase in gastric tissue[2]
Myeloperoxidase, an enzyme found primarily in neutrophil azurophilic granules, has been used extensively as a biochemical marker for granulocyte infiltration into various tissues, including the gastrointestinal tract (Costa et al., 2013, Krawisz et al., 1984). MPO activity was determined using an MPO activity measurement kit by adding 0.2 ml of o-dianisidine hydrochloride and 0.0005% hydrogen peroxide to 4 ml buffer containing 0.2 ml homogenates. MPO activity was assayed at room temperature by measuring the increase in absorbance at 460 nm due to the fluorescent product oxidized by the H2O2-generated redox intermediate. MPO activities were expressed as units per gram of tissue.

---

Cytokine evaluations in gastric tissue[2]
The cytokine levels of IL-6 and TNF-α in gastric tissue were evaluated using ELISA kits according to the manufacturer's instructions. Supernatant of homogenates or cytokine standards (100 μl) were respectively loaded into each well and then followed with biotin conjugated secondary antibodies. To obtain color reaction, streptavidin–HRP and substrate solution were added. The absorbance was measured at 450 nm with an ELISA reader. A standard curve was run on each assay plate using recombinant IL-6 and TNF-α in serial dilution. The results were expressed pg/mg tissue.

---

Determination of NO level in gastric tissue[2]
The level of nitric oxide in the gastric tissue was evaluated as total nitrate/nitrite using Griess reagent (Green et al., 1982) and the operational processes were measured in accordance with the NO kit instructions. Briefly, 50 μl of tissue supernatant was added to 50 μl Griess reagent [0.1% N-(1-naphthyl) ethylenediamine dihydrochloride, 1% sulphanilamide and 2.5% H3PO4] and mixed. After incubation at room temperature for 10 min, the absorbance was measured at 540 nm. The results were expressed as μmol/g protein.

---

Cytokine evaluations in serum[2]
The levels of cytokines (IL-6 and TNF-α) in the serum were analyzed by enzyme-linked immunosorbent assay using ELISA kits for rats according to the manufacturer's instructions. The results were expressed as pg/ml serum.

---

In vitro enzyme/receptor binding assays for (±)-stylopine hydrochloride are not extensively documented. Its anti-inflammatory activity can be assessed by measuring cytokine production in activated immune cells. Antimicrobial activity is evaluated using standard microbial growth inhibition assays. Antitumor activity is assessed using cancer cell viability assays.

In vitro cellular assays for (±)-stylopine hydrochloride involve treating immune cells, microbial cultures, or cancer cell lines with varying concentrations of the compound. Anti-inflammatory activity is evaluated by measuring cytokine levels. Antimicrobial activity is assessed by measuring inhibition of microbial growth. Antitumor activity is evaluated by measuring cell viability using MTT or other assays.

Ethanol-induced gastric mucosal damage[2]
Mice were randomly divided into five experimental groups, each containing ten animals. The normal and ulcer control groups received vehicle (0.9% saline) throughout the course of the experiments. The prevention groups received (ip) different doses of THC (10 and 20 mg/kg, dissolved in 0.9% saline) and cimetidine (100 mg/kg, reference drug, dissolved in 0.9% saline) respectively for a period of 3 days. After fasting for 24 h prior to the experiment, mice were fed orally with 75% ethanol (0.5 ml/100 g body weight) to induce the acute ulcer, while the normal group received water only (Mei et al., 2012). Four hours after induction, blood samples were collected from the retro-orbital plexus of each animal and were then centrifuged for 10 min at 2500 g to obtain clear sera which were stored at − 80 °C before use (Choi et al., 2010). After the mice were euthanized, the stomachs were rapidly removed, opened along the greater curvature and rinsed with ice-cold saline to remove the gastric contents and blood clots in order to assess the extent of gastric damage. Thereafter, each stomach was dichotomised, with one moiety of stomach immersed in 10% formaldehyde for histological evaluation and gastric tissue from the other moiety stored at − 80 °C for biochemical determinations.[2]

---

Determination of gastric ulcer index[2]
The degree of gastric mucosal damage was evaluated from digital pictures, and rated for gross pathology according to the ulcer score scales as previously described (Salga et al., 2012). The lesions were scored as follows: 0: no lesions; 0.5: slight hyperemia or ≤ 5 petechiae; 1: ≤ 5 erosions ≤ 5 mm in length; 1.5: ≤ 5 erosions ≤ 5 mm in length and many petechiae; 2: 6–10 erosions ≤ 5 mm in length; 2.5: 1–5 erosions > 5 mm in length; 3: 5–10 erosions > 5 mm in length; 3.5: > 10 erosions > 5 mm in length; 4: 1–3 erosions ≤ 5 mm in length and 0.5–1 mm in width; 4.5: 4–5 erosions ≤ 5 mm in length and 0.5–1 mm in width; 5: 1–3 erosions > 5 mm in length and 0.5–1 mm in width; 6: 4 or 5 grade 5 lesions; and 7: ≥ 6 grade 5 lesions; 8: complete lesion of the mucosa with hemorrhage.. The sum of the total scores was divided by the number of animals to obtain the mean ulcer index for each group.

---

In vivo animal experiments for (±)-stylopine hydrochloride are not extensively documented. If used in animal models, typical protocols would involve administering the compound to models of inflammation, infection, or cancer and evaluating efficacy by measuring inflammatory markers, microbial load, or tumor growth.

Pharmacokinetic data for (±)-stylopine hydrochloride are limited. The compound has a molecular weight of 359.80 and a molecular formula of C19H18ClNO4. Purity is ≥98.5%. Its absorption, distribution, metabolism, and excretion properties have not been characterized.

Toxicological data for (±)-stylopine hydrochloride are limited. As a natural product-derived compound, it is generally considered to have moderate toxicity, but comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.

[1]. Anti-inflammatory effect of tetrahydrocoptisine from Corydalis impatiens is a function of possible inhibition of TNF-α, IL-6 and NO production in lipopolysaccharide-stimulated peritoneal macrophages through inhibiting NF-κB activation and MAP.

[2]. Protective effect of tetrahydrocoptisine against ethanol-induced gastric ulcer in mice. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):21-9.

(±)-Stylopine hydrochloride (Tetrahydrocoptisine hydrochloride) (CAS#: 96087-21-7) has the molecular formula C19H18ClNO4 and a molecular weight of 359.80. It is an alkaloid with anti-inflammatory, antimicrobial, and antitumor activities. Purity is ≥98.5%. The compound is for research use only.

C19H18CLNO4

359.80

359.092

96087-21-7

(±)-Stylopine;4312-32-7;(-)-Stylopine;84-39-9; 84-39-9 (S-isomer); 4312-32-7 (racemic); 7461-02-1 (racemic)

131864060

Typically exists as white to off-white solids at room temperature

Corydalis tubers

1

5

0

25

502

0

Cl.O1COC2C1=CC1CCN3CC4C(CC3C=1C=2)=CC=C1C=4OCO1

WZUQSTMUNWBERD-UHFFFAOYSA-N

InChI=1S/C19H17NO4.ClH/c1-2-16-19(24-10-21-16)14-8-20-4-3-12-6-17-18(23-9-22-17)7-13(12)15(20)5-11(1)14;/h1-2,6-7,15H,3-5,8-10H2;1H

5,7,17,19-tetraoxa-13-azahexacyclo[11.11.0.02,10.04,8.015,23.016,20]tetracosa-2,4(8),9,15(23),16(20),21-hexaene;hydrochloride

Stylopine hydrochloride; 96087-21-7; 5,7,17,19-tetraoxa-13-azahexacyclo[11.11.0.02,10.04,8.015,23.016,20]tetracosa-2,4(8),9,15(23),16(20),21-hexaene;hydrochloride; ( inverted exclamation markA)-Stylopine (hydrochloride); 6,7,12b,13-Tetrahydro-4H-[1,3]dioxolo[4',5':7,8]isoquinolino[3,2-a][1,3]dioxolo[4,5-g]isoquinoline hydrochloride; DL-Stylopine (hydrochloride);

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light.

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : 2 mg/mL (5.56 mM)
H2O : < 0.1 mg/mL

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)